mRNA Vaccine Production Facility Engineering

Popular Products

Design-Build Services for Biotechnology Manufacturing Facilities

Media and Buffer Preparation Vessel Manufacturing

Risk-Based Biopharmaceutical Plant and Cleanroom Design

mRNA Vaccine Manufacturing Facility Design-Build

Turnkey Biopharmaceutical Plant Design and Construction

Process-Driven Biopharmaceutical Equipment Integration

Our specialized mRNA vaccine production facility engineering delivers cGMP-compliant, RNase-controlled integrated plant design and construction solutions dedicated to nucleic acid therapeutic manufacturing. Covering greenfield new-build campuses and brownfield retrofitting projects, the full-service engineering scope spans master site planning, risk-segregated cleanroom zoning, dedicated process utility design, bioprocess equipment layout integration, waste biosafety treatment and intelligent environmental monitoring systems. The facility is engineered to accommodate the complete mRNA workflow: plasmid DNA fermentation, IVT reaction, mRNA purification, microfluidic LNP encapsulation, sterile formulation, aseptic fill-finish and temperature-controlled cold storage. Addressing core industry-specific risks including RNase contamination, mRNA degradation, residual DNA/dsRNA impurities and nanoparticle consistency deviation, the engineering design establishes strict physical and airflow isolation between different production stages. Scalable for clinical pilot batches and large-scale commercial mass manufacturing, the complete engineering package eliminates incompatibility between building structure and nucleic acid process requirements, shortens project delivery timelines and creates fully audit-ready infrastructure to support IND submission, global regulatory inspection and long-term vaccine commercial supply chains.

Core Design Philosophy

We adhere to the core engineering principle of RNase-Free Hierarchical Containment, Low-Shear Process Compatibility, and Modular Regulatory Scalability, synchronizing spatial partitioning, personnel/material flow and utility distribution to protect fragile nucleic acid molecules while enabling flexible multi-product campaign switching and phased capacity expansion.

RNase Barrier Segregation Architecture: Deploy independent pressure cascades, dedicated gowning zones and fully separated logistics corridors for pDNA synthesis, in vitro transcription, mRNA purification and LNP formulation areas; single-use closed fluid transfer minimizes open exposure and cross-area RNase migration risks.

Nucleic Acid-Friendly Environmental Control: Optimize HVAC temperature, humidity and air change rates to avoid mRNA hydrolysis; design low-turbulence transfer pipelines and microfluidic mixing layouts to reduce shear force that breaks nucleic acid strands.

Single-Use-Oriented Facility Layout: Reserve ample space for disposable consumable storage and handling, reduce the scope of fixed piping requiring repeated CIP/SIP validation and lower long-term sanitization compliance workload.

Expandable Standardized Modular Framework: Pre-configure unified utility manifolds, equipment foundation zones and pipeline trenches to support future production line expansion and new mRNA vaccine pipeline insertion without large-scale civil demolition.

Authoritative Global Compliance System

All civil engineering standards, cleanroom classification, utility specifications and monitoring control logic fully align with FDA and EMA dedicated mRNA manufacturing guidance, ICH quality guidelines and ISPE biopharmaceutical facility norms. Complete risk assessment and validation documentation packages are delivered to streamline factory certification and cross-border drug registration.

Nucleic Acid-Specific GMP Compliance Framework: Enforce rigorous bioburden, endotoxin and residual impurity control design; all facility contact materials and consumable storage areas adopt RNase-certified low-adsorption finishes to prevent nucleic acid degradation and cross-contamination.

Full Lifecycle 21 CFR Part 11 Data Integrity: Centralized monitoring and automation systems capture immutable electronic records for cleanroom environment, equipment operation, LNP mixing parameters and filling batches, forming complete retrievable audit trails for regulatory review.

Cross-Regional Regulatory Adaptability: Engineering drawings, qualification protocols and risk analysis documents comply with European, American and Asian regional inspection standards, simplifying multi-market vaccine registration procedures.

Full-Lifecycle Facility Engineering Delivery Services

We provide one-stop integrated engineering support from pre-project feasibility evaluation, specialized nucleic acid facility design, construction supervision, equipment coordination to post-completion qualification and long-term technical consultation.

Regulatory Feasibility & Master Layout Planning: Conduct local biopharma supervision policy, utility load and biosafety waste discharge research, output phased construction master plans and risk zoning schemes matched to target annual vaccine output.

Classified Cleanroom & Specialized Utility Engineering: Complete Grade A/B/C/D RNase-controlled cleanroom construction, dedicated WFI, pure steam, ultra-clean compressed air, low-temperature chilled water and biological waste inactivation treatment system design and construction.

Process Equipment Integration & Automation Deployment: Coordinate layout matching of pDNA bioreactors, mRNA TFF/chromatography skids, microfluidic LNP mixing platforms and robotic aseptic filling lines; deploy unified MES and real-time particle size monitoring systems.

Consolidated Validation Dossiers & Sustained Technical Backing: Deliver full facility qualification, equipment IQ/OQ/PQ and process validation master files; provide long-term facility renovation consultation, process optimization and production capacity upgrade technical support.